K. B. Nolop

23.8k citations

64 papers · 7.3k indexed · 4 hit papers · h-index 32

Molecular Biology top 2%
Oncology top 0.5%
Pulmonary and Respiratory Medicine top 1%
Physiology top 2%
Cancer Research top 2%

Co-authors: Grant A. McArthur Keith T. Flaherty Igor Puzanov Paul B. Chapman Antoni Ribas Jeffrey A. Sosman Richard J. Lee Kevin B. Kim
Topics: Melanoma and MAPK Pathways (21 papers)Asthma and respiratory diseases (15 papers)Allergic Rhinitis and Sensitization (9 papers)
Cited by: Immunology and Allergy Oncology Cancer Research
Journals: New England Journal of Medicine Journal of Clinical Oncology Blood
Partner nations: United States Australia United Kingdom

In The Last Decade

K. B. Nolop

64 papers receiving 7.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

2010 2.6k citations Keith T. Flaherty, Igor Puzanov et al. profile →
Vemurafenib: the first drug approved for BRAF-mutant cancer

2012 594 citations Gideon Bollag, James Tsai et al. Nature Reviews Drug Discovery profile →
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer

2015 513 citations Scott Kopetz, Jayesh Desai et al. Journal of Clinical Oncology profile →
Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study

2015 433 citations Nicholas Butowski, Howard Colman et al. Neuro-Oncology profile →

Peers

Countries citing papers authored by K. B. Nolop

Since Specialization

Citations

This map shows the geographic impact of K. B. Nolop's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. B. Nolop with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. B. Nolop more than expected).

Fields of papers citing papers by K. B. Nolop

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. B. Nolop. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. B. Nolop. The network helps show where K. B. Nolop may publish in the future.

Co-authorship network of co-authors of K. B. Nolop

This figure shows the co-authorship network connecting the top 25 collaborators of K. B. Nolop. A scholar is included among the top collaborators of K. B. Nolop based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. B. Nolop. K. B. Nolop is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancerbreakdown → 2015 ·Journal of Clinical Oncology ·Scott Kopetz,Jayesh Desai,Emily Chan,J. Randolph Hecht,Peter J. O’Dwyer,Dipen M. Maru,Van K. Morris,Filip Jankú,Arvind Dasari,Woonbok Chung,Jean‐Pierre J. Issa,Peter Gibbs,Brian P. James,Garth Powis,K. B. Nolop,Suman Bhattacharya,Leonard B. Saltz	513
2	Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II studybreakdown → 2015 ·Neuro-Oncology ·Nicholas Butowski,Howard Colman,John de Groot,Antonio Omuro,Lakshmi Nayak,Patrick Y. Wen,Timothy F. Cloughesy,Adhirai Marimuthu,Sam Haidar,Arie Perry,Jason T. Huse,Joanna J. Phillips,Brian L. West,K. B. Nolop,Henry H. Hsu,Keith L. Ligon,Annette M. Molinaro,Michael D. Prados	433
3	Long-term outcome in BRAFV600E melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression 2015 ·European Journal of Cancer ·Igor Puzanov,Ravi K. Amaravadi,Grant A. McArthur,Keith T. Flaherty,Paul B. Chapman,Jeffrey A. Sosman,Antoni Ribas,Mark Shackleton,Patrick Hwu,Bartosz Chmielowski,K. B. Nolop,Paul Lin,Kevin B. Kim	52
4	Clinical Responses to Vemurafenib in Patients with Metastatic Papillary Thyroid Cancer Harboring BRAF ^V600E Mutation 2013 ·Thyroid ·Kevin B. Kim,Maria E. Cabanillas,Alexander J. Lazar,Michelle D. Williams,(unknown),(unknown),K. B. Nolop,Richard J. Lee,Steven I. Sherman	157
5	Vemurafenib: the first drug approved for BRAF-mutant cancerbreakdown → 2012 ·Nature Reviews Drug Discovery ·Gideon Bollag,James Tsai,Jiazhong Zhang,Chao Zhang,Prabha N. Ibrahim,K. B. Nolop,Peter Hirth	594
6	Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAF^V600E mutation 2010 ·International Journal of Cancer ·Jeanne Tie,Peter Gibbs,Lara Lipton,Michael Christie,Robert N. Jorissen,Antony W. Burgess,Matthew Croxford,Ian T. Jones,Rachel Langland,Suzanne Kosmider,Daniel J. McKay,Gideon Bollag,K. B. Nolop,Oliver M. Sieber,Jayesh Desai	182
7	Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer 2009 ·Journal of Clinical Oncology ·Keith T. Flaherty,Igor Puzanov,Jeffrey A. Sosman,(unknown),Antoni Ribas,Grant A. McArthur,(unknown),Joseph F. Grippo,K. B. Nolop,Paul B. Chapman	163
8	Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler 2001 ·Annals of Allergy Asthma & Immunology ·Michael Noonan,Jill P. Karpel,George Bensch,Joe Ramsdell,D. Robert Webb,K. B. Nolop,Barry N. Lutsky	78
9	Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate 2001 ·Annals of Allergy Asthma & Immunology ·Robert A. Nathan,Anjuli Nayak,David F. Graft,Michael B. Lawrence,(unknown),Tahir Ahmed,James Wolfe,(unknown),K. B. Nolop,Judy E. Harrison	44
10	Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma 2000 ·Journal of Allergy and Clinical Immunology ·James P. Kemp,Robert Berkowitz,S. David Miller,John J. Murray,K. B. Nolop,Judy E. Harrison	70
11	Effect of Mometasone Furoate on Early and Late Phase Inflammation in Patients with Seasonal Allergic Rhinitis 1998 ·Annals of Allergy Asthma & Immunology ·Marianne Frieri,(unknown),(unknown),(unknown),(unknown),(unknown),Giorgio R. Sansone,(unknown),(unknown),Myron Zitt,(unknown),K. B. Nolop	36
12	The responsiveness of disease-specific and generic health measures to changes in the severity of asthma among adults. 1998 ·Quality of Life Research ·John E. Ware,James P. Kemp,David A. Buchner,Alan E. Singer,K. B. Nolop,Thomas F. Goss	82
13	A Comparison of Double-Strength Beclomethasone Dipropionate (84 μg) MDI With Beclomethasone Dipropionate (42 μ) MDI in the Treatment of Asthma 1997 ·CHEST Journal ·Robert A. Nathan,K. B. Nolop,Francis M. Cuss,Richard Lorber	16
14	Comparison of Once Daily Mometasone Furoate (Nasonex) and Fluticasone Propionate Aqueous Nasal Sprays for the Treatment of Perennial Rhinitis 1997 ·Annals of Allergy Asthma & Immunology ·Michael Mandl,K. B. Nolop,Barry N. Lutsky	78
15	Dose Ranging Study of Mometasone Furoate (Nasonex) in Seasonal Allergic Rhinitis 1997 ·Annals of Allergy Asthma & Immunology ·Edwin A. Bronsky,Donald W. Aaronson,Robert Berkowitz,Paul Chervinsky,David F. Graft,Harold B. Kaiser,(unknown),Robert A. Nathan,David S. Pearlman,Paul H. Ratner,Jeffrey Adelglass,(unknown),Julius van Bavel,Frank C. Hampel,W. Stricker,(unknown),Francis M. Cuss,K. B. Nolop	55
16	Once‐daily mometasone furoate aqueous nasal spray (Nasonex®) in seasonal allergic rhinitis: an active‐ and placebo‐controlled study 1996 ·Allergy ·Jacques Hébert,K. B. Nolop,Barry N. Lutsky	74
17	Endothelin-1 from Pulmonary Artery and Micro vessels Acts on Vascular and Airway Smooth Muscle 1989 ·Journal of Cardiovascular Pharmacology ·Una Ryan,Marilyn K. Glassberg,K. B. Nolop	21
18	Glucose utilizationin vivo by human pulmonary neoplasms 1987 ·Cancer ·K. B. Nolop,(unknown),Lars Brudin,R. P. Beaney,Thomas Krausz,Terry Jones,Judith M. Hughes	214
19	A Comparison of ^99m Tc-DTPA and ^113m In-DTPA Aerosol Clearances in Humans: Effects of Smoking, Hyperinflation, and in vitro Oxidation 1987 ·American Review of Respiratory Disease ·K. B. Nolop,David Maxwell,John Fleming,(unknown),Judith M. Hughes,D. Royston	26
20	Increased Pulmonary Transvascular Protein Flux after Canine Cardiopulmonary Bypass 1986 ·American Review of Respiratory Disease ·S. Braude,K. B. Nolop,John Fleming,Thomas Krausz,Kenneth M. Taylor,David Royston	55

About K. B. Nolop

K. B. Nolop is a scholar working on Immunology and Allergy, Oncology and Sensory Systems, having authored 64 papers that have together received 7.3k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (21 papers), Asthma and respiratory diseases (15 papers) and Allergic Rhinitis and Sensitization (9 papers). The work is most often cited by research in Immunology and Allergy (746 citations), Oncology (3.4k citations) and Cancer Research (908 citations). K. B. Nolop has collaborated with scholars based in United States, Australia and United Kingdom. Frequent co-authors include Grant A. McArthur, Keith T. Flaherty, Igor Puzanov, Paul B. Chapman, Antoni Ribas, Jeffrey A. Sosman, Richard J. Lee, Kevin B. Kim, Peter J. O’Dwyer and Joseph F. Grippo. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact